Clearance Summary
TRICAT RIA (ADRENALIN/NORADRENALIN/DOPAMINE); KATCOMBI RIA (ADRENALIN/NORADRENALIN); NORADRENALIN RIA received FDA 510(k) clearance under submission number K051969, sponsored by Ibl GmbH. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 2005-10-03.
- Submission: K051969
- Applicant / Sponsor: Ibl GmbH
- Clearance pathway: Traditional
- Review panel: Clinical Chemistry
- Device class: Class I
- Regulation citation: 21 CFR 862.1165
- Decision date: 2005-10-03
Classification & Regulation
This clearance is catalogued under FDA product code CHQ and 21 CFR 862.1165, within the Clinical Chemistry review panel as a Class I device.